Baseline Characteristics
| Characteristic | All patients (n = 25) |
|---|---|
| Age, year (range) | 49 (30–72) |
| Gender: male, no. (%) | 11 (44) |
| Race | |
| Caucasian, no. (%) | 22 (88) |
| Asian, no. (%) | 1 (4) |
| Black, no. (%) | 0 (0) |
| Latino/Hispanic, no. (%) | 1 (4) |
| Other, no. (%) | 1 (4) |
| Diagnosis | |
| Glioblastoma, no. (%) | 13 (52) |
| Anaplastic astrocytoma, no. (%) | 7 (28) |
| Anaplastic oligodendroglioma, no. (%) | 2 (8) |
| Unspecified high grade glioma, no. (%) | 2 (8) |
| Gliosarcoma, no. (%) | 1 (4) |
| Performance status, KPS (range) | 80 (50–100) |
| Number of prior therapies, median (range) | 4 (1–9) |
| Previously received bevacizumab, no. (%) | 19 (76) |
| MGMT status | |
| Methylated, no. (%) | 4 (16) |
| Unmethylated, no. (%) | 12 (48) |
| Unknown, no. (%) | 9 (36) |
| IDH1 Status | |
| IDH1 Mutated, no. (%) | 10 (40) |
| IDH1 Wild Type, no. (%) | 9 (36) |
| Unknown, no. (%) | 6 (24) |
| Number of mutations by MSK-Impact, median (range) | 7 (3–58) |
| PD-1 inhibitor | |
| Pembrolizumab, no. (%) | 25 (100) |
| Number of doses administered, median (range) | 3 (1–14) |
| Concomitant therapy | |
| Pembrolizumab monotherapy, no. (%) | 6 (24) |
| Bevacizumab, no. (%) | 17 (68) |
| Cytotoxic chemotherapy + bevacizumab, no. (%) | 2 (8) |
| Receiving dexamethasone at time of first dose, no. (%) | 14 (56%) |